These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24135847)

  • 1. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Wang F; Gao H; Li C; Bai J; Lu R; Cao L; Wu Y; Hong L; Wu Y; Lan X; Zhang Y
    J Neurooncol; 2014 Jan; 116(1):83-8. PubMed ID: 24135847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
    BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
    BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
    Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
    Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
    J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
    Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
    Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
    Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
    Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
    Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.
    Wu ZB; Zheng WM; Su ZP; Chen Y; Wu JS; Wang CD; Lin C; Zeng YJ; Zhuge QC
    J Neurooncol; 2010 Aug; 99(1):25-32. PubMed ID: 20063113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
    Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of prolactinomas.
    Molitch ME; Thorner MO; Wilson C
    J Clin Endocrinol Metab; 1997 Apr; 82(4):996-1000. PubMed ID: 9100563
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of pituitary tumors: dopamine agonists.
    Iván G; Szigeti-Csúcs N; Oláh M; Nagy GM; Góth MI
    Endocrine; 2005 Oct; 28(1):101-10. PubMed ID: 16311416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.